2 completed, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow CARE Pharma Shanghai Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH CAN106 20 mg/kg, CAN106 40 mg/kg, CAN106 80 mg/kg - PNH, Hemolysis | Phase 1 / Phase 2 | Unknown | CARE Pharma Shanghai Ltd. | 78 | 2022-03-25 | 2022-09-14 |
| Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China Paroxysmal Nocturnal Hemoglobinuria, Natural History Study | Completed | CARE Pharma Shanghai Ltd. | 67 | 2021-11-25 | 2022-07-05 | |
| Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects CAN106, Placebo - PNH | Phase 1 | Completed | CARE Pharma Shanghai Ltd. | 31 | 2021-02-22 | 2022-05-25 |
Hemoglobinuria, Paroxysmal (1) · Hemolysis (1)
China (2) · Singapore (1)
Bing Han, MD (2) · Hongzhong Liu, MMed (1)